Subject
General Pharmacology, Toxicology and Pharmaceutics
Reference8 articles.
1. D’Amico A , Mercuri E , Tiziano FD , et al . Spinal muscular atrophy. Orphanet J Rare Dis 2011;6:71. doi:10.1186/1750-1172-6-71
2. Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data;Erdos;Eur J Paediatr Neurol,2022
3. Treatment of adult spinal muscular atrophy: overview and recent developments;Brakemeier;Curr Pharm Des,2022
4. EMA . Summary of product characteristics: nusinersen. 2017. Available: https://www.ema.europa.eu/en/documents/product-information/spinraza-epar-product-information_en.pdf
5. EMA . Summary of product characteristics: onasemnogene abeparvovec. 2020. Available: https://www.ema.europa.eu/en/documents/product-information/zolgensma-epar-product-information_en.pdf